^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD79B mutation

    i
    Other names: CD79B, B-Cell Antigen Receptor Complex-Associated Protein Beta Chain, CD79b Molecule, Immunoglobulin-Associated Beta, Immunoglobulin-Associated B29 Protein, B-Cell-Specific Glycoprotein B29, Ig-Beta, IGB, B29, CD79b Antigen (Immunoglobulin-Associated Beta), CD79B Antigen (Immunoglobulin-Associated Beta), CD79b Antigen, AGM6
    Entrez ID:
    974
    Related biomarkers:
    Expression
    Mutation
    Apply
    Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111-218) (NCT05068440)
    Phase 2
    BeiGene
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    08/11/2021
    Primary completion :
    10/21/2025
    Completion :
    10/21/2025
    CD79B
    |
    CD79B mutation • CD79B mutation
    |
    Brukinsa (zanubrutinib)
    ZR-CHOP in DLBCL With Specific Gene Abnormality (NCT05290337)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    03/22/2022
    Initiation :
    01/04/2022
    Primary completion :
    01/04/2024
    Completion :
    01/04/2026
    TP53 • MYC • MYD88 • CD79B
    |
    TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib)
    Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies (NCT04994626)
    Phase 2
    Chinese Academy of Medical Sciences
    Not yet recruiting
    Last update posted :
    08/06/2021
    Initiation :
    10/01/2021
    Primary completion :
    04/01/2022
    Completion :
    07/01/2025
    CD20 • MYD88 • CD79B • CD79A
    |
    CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab)
    Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma (PROTEOM) (NCT04183569)
    Phase N/A
    University Hospital, Bordeaux
    Unknown status
    Last update posted :
    04/29/2020
    Initiation :
    02/19/2019
    Primary completion :
    05/01/2020
    Completion :
    05/01/2020
    BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1
    |
    CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation